TY - JOUR
T1 - Management of moderate to severe chronic low back pain with buprenorphine buccal film using novel bioerodible mucoadhesive technology
AU - Pergolizzi, Joseph V.
AU - Raffa, Robert B.
AU - Fleischer, Charles
AU - Zampogna, Gianpietro
AU - Taylor, Robert
PY - 2016/10/31
Y1 - 2016/10/31
N2 - With a global prevalence of ~9%–12%, low back pain (LBP) is a serious public health issue, associated with high costs for treatment and lost productivity. Chronic LBP (cLBP) involves central sensitization, a neuropathic pain component, and may induce maladaptive coping strategies and depression. Treating cLBP is challenging, and current treatment options are not fully satisfactory. A new BioErodible MucoAdhesive (BEMA®) delivery system for buprenorphine has been developed to treat cLBP. The buccal buprenorphine (BBUP) film developed for this product (Belbuca™) allows for rapid delivery and titration over a greater range of doses than was previously available with transdermal buprenorphine systems. In clinical studies, BBUP was shown to effectively reduce pain associated with cLBP at 12 weeks with good tolerability. The most frequently reported side effects with the use of BBUP were nausea, constipation, and vomiting. There was no significant effect on the QT interval vs placebo. Chronic pain patients using other opioids can be successfully rotated to BBUP without risk of withdrawal symptoms or inadequate analgesia. The role of BBUP in managing cLBP remains to be determined, but it appears to be a promising new product in the analgesic arsenal in general.
AB - With a global prevalence of ~9%–12%, low back pain (LBP) is a serious public health issue, associated with high costs for treatment and lost productivity. Chronic LBP (cLBP) involves central sensitization, a neuropathic pain component, and may induce maladaptive coping strategies and depression. Treating cLBP is challenging, and current treatment options are not fully satisfactory. A new BioErodible MucoAdhesive (BEMA®) delivery system for buprenorphine has been developed to treat cLBP. The buccal buprenorphine (BBUP) film developed for this product (Belbuca™) allows for rapid delivery and titration over a greater range of doses than was previously available with transdermal buprenorphine systems. In clinical studies, BBUP was shown to effectively reduce pain associated with cLBP at 12 weeks with good tolerability. The most frequently reported side effects with the use of BBUP were nausea, constipation, and vomiting. There was no significant effect on the QT interval vs placebo. Chronic pain patients using other opioids can be successfully rotated to BBUP without risk of withdrawal symptoms or inadequate analgesia. The role of BBUP in managing cLBP remains to be determined, but it appears to be a promising new product in the analgesic arsenal in general.
KW - BEMA
KW - Buccal
KW - Buprenorphine
KW - Chronic low back pain
KW - Drug delivery Belbuca
KW - Transmucosal
UR - http://www.scopus.com/inward/record.url?scp=84994475204&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84994475204&partnerID=8YFLogxK
U2 - 10.2147/JPR.S87952
DO - 10.2147/JPR.S87952
M3 - Review article
C2 - 27826213
AN - SCOPUS:84994475204
SN - 1178-7090
VL - 9
SP - 909
EP - 916
JO - Journal of Pain Research
JF - Journal of Pain Research
ER -